Introduction
Self measurement of blood glucose (SMBG) is an essential element in the treatment of diabetic patients. It provides immediate information on blood glucose (BG) values to patients and health care professionals and enables them to optimise glucose control thereby reducing the risk for complications [1, 2] . Several studies documented the clinical advantage of SMBG in type 1 diabetes patients [3] [4] [5] [6] [7] and there is rising evidence of similar benefits in patients with type 2 diabetes [8] [9] [10] . Owing to the increasing prevalence of diabetic patients [11] and the beneficial effects of blood glucose measurement in this population one can expect SMBG to be even more widely used in the future. This highlights the importance of providing reliable measurements of SMBG-devices used in clinical routine. Accuracy of devices can be assessed with regard to right or wrong therapeutic decision based on a given blood glucose value obtained from an SMBG-device. This is achieved by using the error grid analysis (EGA), which divides a scatter plot comparing reference values and SMBG values into five regions of different clinical significance/interpretation. A more technical and mathematical approach to determine accuracy as well as precision is to calculate the relative deviation compared to an accepted reference method [12] . Furthermore the compliance with the requirements determined by the International Organization for Standardization (ISO 15197:2003 [13] ) is an accepted measure for the quality of clinically used SMBG devices. Independently whatever approach of analysis is used the underlying principle is a good agreement between the reference and the SMBG under investigation. In clinical practice patients are often confronted with a lack of information on reliability of their blood glucose measurements. Whether the degree of deviation is within an established range is often unclear, since the manufacturers' specification on accuracy and precision is usually based on assessments with so called "golden lots". This includes test strips known to have a particularly high accuracy. Therefore, we prospectively assessed three frequently used glucose meters in clinical practice. Importantly, the corresponding manufactures did not financially support this evaluation.
Methods

Study design and patients
This was a prospective single centre study performed at the Diabetes Section of the Inselspital, the University Hospital of Bern, Switzerland between October 2009 and September 2010. The study followed the guidelines of good clinical practice, the Swiss health laws and the ordinance on clinical research. Each participant gave informed consent, and the study was approved by the local ethics committee in Bern, Switzerland. A total of 150 participants attending the outpatient clinic for routine control were enrolled in this clinical study. Inclusion criteria were diabetes mellitus or impaired glucose tolerance according to current guidelines [14] and age of more than 18 years.
Blood glucose measurements
Capillary blood samples were always collected by the same experienced person. This procedure was chosen in order to minimise user dependant pre-analytical bias. The area of measurement was disinfected before pricking and the first drop of blood was removed with a sterile tissue. All the measurements were carried out with one single subsequent drop from the same area. The drop was applied to the stripes of the following four devices in random order: Contour ® (Bayer Diabetes Care, Zürich, Switzerland), AccuCheck ® aviva (Roche Diagnostics, Rotkreuz, Switzerland), Free-Style ® lite (Abbott Diabetes Care, Baar, Switzerland) and the HemoCue ® Glucose 201+ System (HemoCue ® AB, Ängelholm, Sweden), which uses the glucose dehydrogenase method and was defined as the reference method in this study [15] . For statistical analysis plasma equivalent glucose readings were used. 
Results
In total 59 female and 91 male patients were included in this analysis. The mean age was 49.3 ± 1.3 years and mean HbA 1c was 7.5 ± 0.1%. Overall Mean Absolute Relative Deviation (MARD) was 10.1 ± 0.65%, 7.0 ± 0.62% and 7.8 ± 0.48% for Contour ® , Accu-Chek ® and Free-Style ® , respectively. Significant differences were detected between Contour ® and Accu-Chek ® (p <0.001) and between Contour ® and Free-Style ® (p = 0.001), whereas MARD was similar for Accu-Chek ® and Free-Style ® (p = 0.67). Maximal observed deviations were 42%, 59% and 29% for Contour ® , Accu-Chek ® and FreeStyle ® , respectively. In the range above 75mg/dl (4.16 mmol/l) MARD was significantly lower compared to the hypoglycaemic range for Accu-Chek ® (6.3 ± 0.46% vs. 15.4 ± 4.7%, p <0.001) and Free-Style ® (7.4 ± 0.48% vs. 12.7 ± 1.91%, p = 0.016), whereas a similar trend but no significant difference between the two ranges was detected for Contour ® 9.9 ± 0.62% vs. 12.8 ± 3.7%, p = 0.2). Figure 1 (0.7%) and Accu-Chek ® (1.3%). Overall 99.3% of the 450 readings were allocated in zones A or B and could therefore be considered as clinically accurate. 
Mean absolute relative deviation
In the overall analysis MARD values in our study were comparable with recent studies, corroborating the validity and results of our analysis [19, 20] n = number of total SMBG readings. Data are number of SMBG readings in each zone (% of total readings). Zone A, glucose levels within ±20% of those found with the reference method leading to clinically correct treatment decisions; Zone B, deviation between device under investigation and reference method is more than 20% but without serious clinical consequences; Zone C, SMBG values would result in unnecessary treatment (overcorrecting acceptable glucose levels); Zone D represents a failure to detect and treat abnormal blood glucose levels; Zone E is an erroneous treatment zone, in which treatment decisions would be unsuitable (confusing hypo-and hyperglycemia). Data are number of SMBG readings within pre-specified deviation limits in the range below and above 75 mg/dl (4.16 mmol/l) and number of SMBG readings meeting the ISO 15197:2003 accuracy criteria (defined as ±15 mg/dl in the glucose range <75 mg/dl and ±20% in the glucose range ≥75 mg/dl) and the ADA criteria (defined as ±5 mg/ dl in the glucose range <75 mg/dl and ±5% in the glucose range ≥75 mg/dl).
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Bland-Altman and error grid analysis
The results obtained from the Bland-Altman plot show that the deviation of all three devices in the low blood glucose ranges mainly results from overestimation of blood glucose values, whereas in the hyperglycaemic range glucose levels tended to be underestimated in relation to the HemoCue as the reference method. This may, therefore, result in an underreporting of hypoglycaemia, which in the case of hypoglycaemia unawareness might have clinical consequences. Nevertheless only three of the 450 measurement values were allocated in Zone D of the EGA, which may result in a wrong therapeutic decision. The remaining values would lead to a similar therapeutic decision according to the EGA. The values in zone A ranged from 94% (Contour ® ) to 96% (Accu-Chek ® and Free-Style ® ), which is comparable to a recent report by Tack and colleagues, who also used commercially available test strips [20] . A study performed by Freckman et al. showed somewhat higher values in zone A, which might be explained by the use of supreme test stripe lots [21] . Interpreting the results of EGA, it has to be kept in mind that deviations of more than 20% seem to be unacceptable from an analytical point of view, but can clinically be acceptable (see Zone B of EGA), because treatment decisions are not negatively affected by this error.
International Organisation of Standardization criteria (ISO 15197:2003)
Accu-Chek ® and Free-Style ® met the ISO criteria (13) of more than 95% of all readings within a deviation of ±20% in the range above 75 mg/dl (4.16 mmol/l) and ±15 mg/ dl (0.83 mmol/l) in the range below 75 mg/dl (4.16 mmol/ l). In contrast, Contour ® showed only 92% of all readings within the ISO limits. Similar results were obtained in a recent study by Tack and colleagues (20) . When applying tighter limits of ±5% in the range above 75 mg/dl (4.16 mmol/l) and ±5 mg/dl (0.28 mmol/l) in the range below 75 mg/dl (4.16 mmol/l) as suggested by the American Diabetes Association [18, 22] none of the three devices would comply with the requirements in either ranges. In contrast to the ISO criteria we found significant differences between the three devices, when applying tighter limits. Only the Accu-Chek ® device showed more than 50% of all readings within the limits suggested by the ADA. Since the error grid analysis showed in only 0.7% of all measurements clinical meaningful deviation it remains questionable whether the application of the tight ADA limits is reasonable in routine clinical practice. Nevertheless, the obvious superiority for the Accu-Chek ® device when it comes to tighter limits, suggests the application of this device in case of usage of the SMBG devices in situations where a reliability as high as possible is absolutely mandatory (as for instance when SMBG devices are used for calibration of continuous glucose monitoring systems).
Interpretation of glucose readings and sources of error
Although the overall mean deviation is acceptable (7-10%) and the devices showed a good clinical performance with regard to the EGA, it must be kept in mind, that we found maximal deviations of up to 60%. Therefore, it is important that patients are critical regarding the plausibility of their measurements and repeat the procedure if concerns arise about the correctness of a measurement. Furthermore, thorough instruction of the patients is absolutely mandatory to reduce user dependent sources of error. Besides adherence to the device manual and recommended measurement condition (i.e. temperature and altitude range), patients should wash and dry their hands before blood sampling, wipe off the first drop of blood and store the strips as indicated by the manufacturer. Contamination of the hands with glucose can lead to pseudohyperglycaemia [23] , whereas wet or sweaty hands could lead to a dilution effect with false
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Strength and limitations
The strength of the present study is the independency from the manufacturers and thus reduction of bias by so called golden lots. Furthermore all measurements were performed with capillary blood from a single finger prick and analysed in a standardised procedure. All blood samples were collected by the same experienced person. Nevertheless, we have to acknowledge several limitations: (i) Since the present study was not industry funded we could only include a comparatively small number of patients. (ii) As reference method we used the HemoCue ® Glucose 201+ system with conversion to plasma levels. This decision was based on a recent report that compared HemoCue ® with the Yellow Springs Instrument (YSI 2300 STAT; YSI). This study suggests that HemoCue ® and the YSI 2300 STAT, which has been used as reference in previous reports assessing SMBG devices in a clinical routine setting [20, 21] , can be used interchangeably for research and clinical purposes [15] . Furthermore, using HemoCue ® offered the possibility of performing all measurements immediately after finger pricking and with the same capillary drop of blood. (iii) Reliability of the measurements is particularly important for the assessment of blood glucose values in the lower range. This study provides only limited data about the performance of the glucose meters in the lower range. We can, therefore, not exclude the fact that the results might be slightly different with a higher incidence of blood glucose values in the hypoglycaemic range. (iv) Since an experienced person performed the blood sampling the present data reflect mainly the technical performance of the devices. Although, if the measurements are carried out according to the manufacture's recommendation -and usually the patients are instructed to do so -these data are also valid in the clinical setting.
Conclusion
From a clinical point of view the three evaluated glucose meters provide sufficient agreement with the reference to warrant a save diabetic therapy when test strips and devices are obtained through regular supply channels. Overall, the Accu-Chek ® and Free-Style ® tended to slightly outperform the Contour ® device. Provided that the measurement is carried out correctly, patients can rely on the results of all three devices, since they assure correct clinical decision making. Nevertheless patients should keep in mind that a mean deviation of about 7-10% must be expected. 
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